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Abstract
Elective surgical patients routinely bathe with chlorhexidine gluconate (CHG) at home days prior to their procedures. However, the impact of
home CHG bathing on surgical site CHG concentration is unclear. We examined 3 different methods of applying CHG and hypothesized that
different application methods would impact resulting CHG skin concentration.
(Received 4 June 2020; accepted 24 August 2020)
Surgical site infections (SSIs) are themost common type of healthcare-
associated infection (HAI) and lead to adverse patient outcomes.1 To
combat SSIs, the use of a skin antiseptic is recommended at least the
night before the surgical procedure.2 The antiseptic properties of
chlorhexidine gluconate (CHG) have been known since 1954, and
its safety and efficacy have been documented in a variety of settings.3,4
CHGactivity is relatedtoCHGskinconcentration.Previousstudies
have shown that a CHG skin concentration≥18.75 μg/mL is inversely
associated with gram-positivemicrobial density on skin. Additionally,
the relative risk of skin contamination with Klebsiella pneumoniae
carbapenemase (KPC)–producing Enterobacteriaceae is decreased
by half in long-term acute-care hospital patients with CHG skin
concentrations ≥128 μg/mL.5,6
CHG no-rinse 2% CHG-impregnated cloths are more effective
than 4% CHG liquid formulae at reducing microbial density on
skin.7 Nonetheless, many elective surgical patients are provided
with the latter, possibly due to lower costs or ease of use.7-9 Few
studies have assessed the ability of 4% CHG liquid formula
application methods to reach published CHG skin concentration
thresholds with notable antimicrobial effectiveness. The objectives
of this study were to determine whether these three 4%CHG liquid
formula application methods differed in preoperative CHG skin
concentration and the proportion of samples that met one or both
key CHG skin concentration thresholds.
Methods
We performed a multicenter, nonrandomized prospective cohort
study of patients undergoing elective hip, knee arthroplasty, spinal
fusion, or laminectomy at Duke University Health System Durham,
North Carolina, Barnes-Jewish Hospital Saint Louis, Missouri, and
Harvard Pilgrim Health Care Institute, Boston, Massachusetts.
Patients were recruited between December 2017 and December
2019 and were excluded if they were <18 years of age, undergoing
emergency surgery, or had a history of the same procedure in the prior
year. Patients were met during the preoperative period on the day of
surgery, informed consent was obtained, and surgical sites were
sampledusingasterile swabmoistenedwithsterilewater for20seconds
which was standardized at each study hospital. CHG concentrations
were determinedusing a semiquantitative colorimetric assaymethod.6
Patients were given different instructions, both written and ver-
bal, during their preoperative appointment on how to bathe with
CHG prior to their surgery with no reminders. Instructions varied
by participating hospital as follows:
Institution/Strategy 1:During daily baths for 5 consecutive days
before and on the day of surgery, do the following steps: (1) shower
normally; (2) apply ¼ cup of 4% CHG Scrub Care soap from the
neck down with a clean washcloth; (3) allow the soap to sit for 2
minutes; and (4) rinse thoroughly and do not wash with any other
soap or cleanser.
Institution/Strategy 2: During daily baths the night before and
day of surgery, do the following steps: (1) shower normally; (2)
moisten the 4% CHG impregnated scrub brush and scrub from
the neck down with the sponge side of the soap pad; (3) let the soap
sit for 3–5 minutes; and (4) rinse thoroughly and do not wash with
any other soap or cleanser.
Institution/Strategy 3: During daily baths for 3 days prior to
surgery, do the following steps: (1) shower normally; (2) wash with
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4% CHG body wash; (3) allow body wash to sit for 1 minute; and
(4) rinse thoroughly and do not wash with any other soap or
cleanser.
Study data were collected, managed, and shared between insti-
tutions using REDCap electronic data capture hosted at Duke
University. The Mann-Whitney U test was used to compare
median CHG skin concentration and age, the Z-score test was used
to compare proportions of patients who met CHG skin concentra-
tion thresholds, and χ2 analysis was used for categorical variables.
A P value of 0.05 was considered significant; all statistical tests were
2-tailed; and all testing was completed using R software (R
Foundation for Statistical Computing, Vienna, Austria). This study
was approved by the institutional review boards of all participat-
ing sites.
Results
In total, 150 patients were enrolled between December 2017 and
December 2019; 11 patients did not have a CHG swab collected
and were excluded. Of the 139 remaining patients, 35 (25%) were
instructed to follow strategy 1 (6 days), 73 (53%) followed strategy
2 (2 days), and 31 (22%) followed strategy 3 (3 days). Of these 139
participants, 77 (55%) were female; the median age of the entire
cohort was 65 years (interquartile range [IQR], 60–72); and 114
(82%) were of white race. In general, the patients in each group
were similar, though a higher proportion of patients undergoing
knee arthroplasty followed strategies 2 and 3 and a lower propor-
tion of patients undergoing laminectomy and spinal fusion
followed strategy 3 (Table 1).
Patients who were instructed to apply 4% CHG for 2 days had a
median CHG skin concentration of 78.1 μg/mL (IQR, 39.1–156.3);
those who applied CHG for 3 days had a median CHG concentra-
tion of 78.1 μg/mL (IQR, 39.1–156.3); and those who applied CHG
for 6 days had a median CHG concentration of 156.3 μg/mL (IQR,
78.1–312.5) (Fig. 1). There was no significant difference between
CHG skin concentrations for 2- and 3-day application methods;
however, both were significantly less than the 6-day application
method (P = .002 and 0.01, respectively).
Similar trends were identified related to each strategies ability
to reach important skin thresholds. Strategy 1 (6 days) achieved
the skin concentration threshold required for reduction of
gram-positive microbial density in 97% of patients and the skin
concentration threshold required for reduction of KPC-producing
Enterobacteriaceae in 60% of patients. Strategy 2 (3 days) achieved
these thresholds in 94% and 32% of patients, and strategy 3 (2 days)
achieved these thresholds in 86% and 28% of patients. There was
no statistical difference in the proportion of samples that met the
≥18.75 μg/mL threshold among the 3 CHG application methods;
however, strategy 1 met the ≥128 μg/mL threshold at significantly
higher proportions than the 2- and 3-day applications (P= .03 and
Table 1. Clinical and Demographic Characteristics
Characteristic
Total
(N= 139), No. (%)
Institution/Strategy 1
(N= 35), No. (%)
Institution/Strategy 2
(N= 73), No. (%)
Institution/Strategy 3
(N= 31), No. (%)
P Value,
1v2, 2v3, 1v3
Age, median y (IQR) 65 (60–72) 64 (53–71) 65 (60–74) 66 (60–72) .27, .88, .37
Sex, female 77 (55) 20 (57) 41 (56) 16 (52) .92, .67, .65
Race .87, .23, .57
White 114 (82) 29 (83) 59 (81) 26 (84)
African American 22 (16) 6 (17) 13 (18) 3 (10)
Asian 3 (2) 0 (0) 1 (1) 2 (6)
Ethnicity .60, .52, .91
Non-Hispanic 137 (99) 35 (100) 72 (99) 30 (97)
Hispanic 2 (1) 0 (0) 1 (1) 1 (3)
Pre-existing skin conditions .71, .77, .22
Total 25 (18) 9 (26) 7 (10) 9 (29)
Eczema 9 (6) 2 (6) 3 (4) 4 (13)
Psoriasis 1 (1) 1 (3) 0 (0) 0 (0)
Skin cancer 4 (3) 0 (20) 1 (1) 3 (10)
Other 12 (9) 7 (11) 3 (5) 2 (13)
Immunocompromised 12 (9) 4 (11) 4 (5) 4 (13) .27, .19, .85
Tobacco 10 (7) 1 (3) 5 (7) 4 (13) .40, .32, .12
Procedure type <.01, .02, <.01
Hip prosthesis 42 (30) 6 (17) 20 (27) 16 (52)
Knee prosthesis 45 (32) 0 (0) 30 (41) 15 (48)
Laminectomy 10 (7) 4 (11) 6 (8) 0 (0)
Spinal fusion 42 (30) 25 (71) 17 (23) 0 (0)
Note. IQR, interquartile range.
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.02, respectively). To control for ease of CHG application based on
surgical site, skin CHG data were also stratified by surgical site;
however, there were no statistically significant differences.
Discussion
Daily bathing with CHG is an effective intervention for reducing
microbial density on skin and is recommended by the CDC as a
preoperative strategy to reduce the risk of a SSI.2,3 Many studies
have compared 2% CHG-impregnated cloths to 4% CHG liquid
applications, but few have assessed the latter’s ability to achieve
CHG skin concentrations for reducing microbial density of
gram-positive bacteria and the risk of contamination with
KPC-producers by half.5,6 Results from our study suggest that
bathing with 4% CHG for more consecutive days provides higher
levels CHG skin concentration on the day of surgery and those lev-
els are more frequently at or above key CHG skin concentration
thresholds.
Our findings could be related to either a CHG build-up effect on
the skin or patients improving their ability to apply CHG with
more applications. Our data are consistent with other assessments
of 4% CHG liquid application methods. Rhee et al7 reported that
two 4% application methods resulted in CHG skin concentrations
of 58.6 and 156.3 μg/mL 6 hours after bathing.
Our study has several limitations. Enrolled patients were not
randomized to arms of the study. In addition, we did not review
clinical outcomes of the enrolled patients due to small sample size.
Finally, patient compliance was monitored by participant verbal
reporting but was not confirmable.
In conclusion, our study supports the theoretical benefit of
certain strategies for preoperative bathing strategies. Repeated
CHG bathing was associated with higher preoperative CHG skin
concentrations. Indeed, improved application strategies for CHG
bathing may be needed to fully demonstrate this intervention as
an evidence-based approach. Subsequent trials to determine the
best methods for pre-operative CHG application should focus
on strategies that optimize preoperative CHG skin concentration.
Acknowledgments.
Financial support. This work was supported by a grant from the Centers for
Disease Control and Prevention (CDC) Prevention Epicenters Program (grant
no. U54CK000483 to D.J.S.).
Conflicts of interest.All authors report no conflicts of interest relevant to this
article.
References
1. Zimlichman E, Henderson D, Tamir O, et al. Health care–associated infec-
tions: a meta-analysis of costs and financial impact on the US Health Care
System: meta-analysis of health care–associated infections. JAMA Intern
Med 2013;173:2039–2046.
2. Berríos-Torres SI, Umscheid CA, Bratzler DW, et al. Centers for Disease
Control and Prevention guideline for the prevention of surgical site infection,
2017. JAMA Surg 2017;152:784–791.
3. Bleasdale SC, TrickWE, Gonzalez IM, Lyles RD, HaydenMK,Weinstein RA.
Effectiveness of chlorhexidine bathing to reduce catheter-associated blood-
stream infections in medical intensive care unit patients. Arch Intern Med
2007;167:2073.
4. Davies GE, Martin JF a R, Rose FL, Swain G. 1: 6-DI-4’-chlorophenyldigua-
nidohexane (“HIBITANE”*): laboratory investigation of a new antibacterial
agent of high potency. Brit J Pharmacol 1954;9:192–196.
5. Lin MY, Blom DW, Hayden MK, et al. The effectiveness of routine daily
chlorhexidine gluconate bathing in reducing Klebsiella pneumoniae carbape-
nemase–producing Enterobacteriaceae skin burden among long-term acute-
care hospital patients. Infect Control Hosp Epidemiol 2014;35:440–442.
6. Popovich KJ, Lyles R, Hayes R, et al. Relation of chlorhexidine gluconate skin
concentration to microbial density on skin of critically ill patients bathed
daily with chlorhexidine gluconate. 2013;33:889–896.
7. Rhee Y, Palmer LJ, Okamoto K, et al.Differential effects of chlorhexidine skin
cleansing methods on residual chlorhexidine skin concentrations and bacte-
rial recovery. Infect Control Hosp Epidemiol 2018;39:405–411.
8. Ritz J, Pashnik B, Padula C, Simmons K. Effectiveness of 2 methods of
chlorhexidine bathing. J Nurs Care Qual 2012;27:171–175.
9. Rhee Y, Hayden MK, Simms A, et al. Impact of measurement and results
feedback of chlorhexidine gluconate (CHG) skin concentrations in medical
intensive care unit (MICU) patients receiving CHG bathing. Open Forum
Infect Dis 2019;6 suppl 2:766–767.
Fig. 1. Chlorhexidine gluconate (CHG) skin concentration by CHG application strat-
egy. Note. *18.75 μg/mL, **128 μg/mL.
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